Novo Nordisk's Ozempic (Semaglutide) 1mg Shows Reduced Risk Of Kidney Disease-Related Events In Phase 3 FLOW Trial
Portfolio Pulse from Benzinga Newsdesk
Novo Nordisk's Ozempic (Semaglutide) 1mg shows reduced risk of kidney disease-related events in Phase 3 FLOW trial. The label extension application has been accepted for FDA review, demonstrating superiority over placebo for all secondary outcomes. Fewer serious adverse events were reported in the Semaglutide group, though there were more discontinuations than placebo.
June 24, 2024 | 5:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novo Nordisk's Ozempic (Semaglutide) 1mg has shown promising results in reducing kidney disease-related events in a Phase 3 trial. The FDA has accepted the label extension application, and the drug demonstrated superiority over placebo for all secondary outcomes. Fewer serious adverse events were reported, though there were more discontinuations in the Semaglutide group.
The positive results from the Phase 3 FLOW trial and the acceptance of the label extension application by the FDA are likely to boost investor confidence in Novo Nordisk. The drug's demonstrated superiority over placebo and fewer serious adverse events are significant positives, although the higher discontinuation rate may be a minor concern.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100